Based on our and other findings that ATM inhibition sensitize tumors to both anti-PD-1 21,22 and anti-Gal9 therapies, it is conceivable that triple combination of ATMi with anti-PD-1 and anti-Gal-9 would produce an even more potent anti-tumor effect. The gene discussed is PDCD1; the disease is neoplasm.